U.S. Court in New Jersey Rejects Novo Nordisk Challenge to Medicare Drug Price Negotiation Program
- August 09, 2024
Drug maker Novo Nordisk failed to prevail in its challenge to the Medicare drug price negotiation program, with the U.S. District Court for the District of New Jersey rejecting the company’s statutory and constitutional claims.
ARTICLE TAGS
You must be logged in to access this content.